Elevai Labs Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
ELAB$1.69+7.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income and Comprehensive Income
Consolidated Statements of Operations and Comprehensive Loss
(Expressed in United States dollar)
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Revenue | $1,712,595 | 766,277 |
| Cost of sales | 578,015 | 318,968 |
| Gross profit | $1,134,580 | 447,309 |
| Expenses | ||
| Depreciation | 10,295 | 5,034 |
| Marketing and promotion | 660,291 | 192,863 |
| Consulting fees | 459,498 | 324,395 |
| Office and administrative | 2,329,067 | 1,019,708 |
| Professional fees | 579,111 | 192,409 |
| Investor relations | 91,009 | 74,003 |
| Research and development | 426,243 | 228,747 |
| Foreign exchange (gain) loss | 6,130 | 2,749 |
| Travel and entertainment | 339,147 | 198,442 |
| Total Expenses | $4,900,791 | 2,238,350 |
| Net loss before other income (expense) | $(3,766,211) | (1,791,041) |
| Other income (expense) | ||
| Listing expense | (450,079) | - |
| Change in fair value of derivative liabilities | (71,266) | (12,754) |
| Interest income | 5,564 | 7,702 |
| Interest expense | (19,525) | (2,629) |
| Loss on sale of equipment | - | (1,546) |
| Net loss | $(4,301,517) | (1,800,268) |
| Other comprehensive income (loss) | ||
| Currency translation adjustment | 91 | (91) |
| Total comprehensive loss | $(4,301,426) | (1,800,359) |
| Basic and diluted loss per share | $(0.400) | (0.189) |
| Weighted average shares outstanding | 10,745,938 | 9,528,863 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.